Moderate to Severe Allergic Asthma Clinical Trial
Official title:
A Randomized, Placebo-Controlled, Phase IIb Dose-Finding Study of CYT003-QbG10, a TLR9-Agonist, in Patients With Moderate to Severe Allergic Asthma Not Sufficiently Controlled on Current Standard Therapy (GINA Steps 3+4)
The purpose of this study is to assess the therapeutic potential and safety/tolerability of
study drug (CYT003) at 3 dose levels versus placebo in patients with persistent moderate to
severe allergic asthma not sufficiently controlled on current standard controller therapy.
Altogether 360 patients randomized to 4 treatment groups will be included. The study
compares three dose strength with placebo. Each patient receives 7 injections of study drug
or undistinguishable placebo. Key outcome measures are patient reported parameters on their
asthma.
n/a
Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT01362621 -
Observational and Epidemiologic Study of the Disease Course and Unmet Needs in Children With Symptomatic Moderate to Severe Allergic Asthma
|
N/A | |
| Recruiting |
NCT06348407 -
A Clinical Study of Omalizumab in the Treatment of Allergic Asthma(ESSENCE)
|